Human peripheral blood monocytes were stained with Mouse Anti-Human CD14 PE‑conjugated Monoclonal Antibody (Catalog # FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078) ...read more
Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (Catalog # 2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent ...read more
Mouse myeloma cell line NS0-derived recombinant human LILRB2/CD85d/ILT4 Gly24-His458 Accession # ACT64556
Detects human LILRB2/CD85d/ILT4 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) ILT1, rhILT2, rhILT3, rhILT6, rhILT7, rhILT11, rhLIR6 or rhLIR8 is observed.
Protein A or G purified from hybridoma culture supernatant
<0.10 EU per 1 μg of the antibody by the LAL method.
Test in a species/application not listed above to receive a full credit towards a future purchase.
The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1‑3). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC) (4). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64 % aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5‑9). It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1 (4, 6). Activation of ILT4 inhibits signaling through Fc gamma RI (4) and Fc epsilon RI (6) and causes DC to become tolerogenic by downregulation of costimulatory molecules (10, 11). ILT4 mediates tolerogenic DC-induced CD4+ T cell energy in vitro and in vivo (10‑12).
Suciu-Foca, N. et al. (2005) Int. Immunopharmacol. 5:7.
Hofmeister, V. and E.H. Weiss (2003) Semin. Canc. Biol. 13:317.
Hunt, J.S. et al. (2005) FASEB J. 19:681.
Finger, N.A. et al. (1998) Eur. J. Immunol. 28:3423.
Borges, L. et al. (1997) J. Immunol. 159:5192.
Colonna, M. et al. (1998) J. Immunol. 160:3096.
Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. 100:8856.
Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
Allen, R.L. et al. (2001) J. Immunol. 167:5543.
Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
Ristich, V. et al. (2005) Eur. J. Immunol. 35:1133.
Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our ILT4/CD85d/LILRB2 Antibody (287219) [Unconjugated] and receive a gift card or discount.